Additional file 1 of Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Additional file 1: Table 1. Category and dosage of target medicine and PD-1 inhibitors. Table 2. Two groups of PD-1 inhibitors combined with targeted therapy. Table 3. Distribution of oligometastasis in the two groups.